Created with Sketch.
Crohn’s & Colitis Foundation Perspectives
8 minutes | Jun 30, 2022
Crohn’s & Colitis Congress 2022: A Look at Diet & Nutrition Therapies
Host: Jennifer Caudle, DO Guest: Maitreyi Raman , MD, MSc, FRCPC Diet and nutrition is known to play a large role in the onset and treatment of IBD. So what were some of the trending sessions focusing on diet and nutrition at the 2022 Crohn’s & Colitis Congress? Join Dr. Jennifer Caudle as she speaks with Dr. Maitreyi Raman to explore the latest research advancements in diet therapies.
7 minutes | Apr 21, 2022
Crohn's & Colitis Congress 2022: Looking Back & Looking Ahead with the 2023 Chair
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Peter D. Higgins, MDm PhD What were some of the key takeaways from the 2022 Crohn's & Colitis Congress, and what's in store for next year’s conference? Hear from the incoming 2023 Congress Chair Dr. Peter D. Higgins.
7 minutes | Apr 8, 2022
Crohn's & Colitis Congress 2022: Combating Challenges for Pediatric Patients
Host: Jennifer Caudle, DO Guest: Ashish S. Patel, MD Treating IBD in our pediatric patients can be challenging, which is why creating a strong partnership between care teams and patients’ families is key. Fortunately, that was a central focus of the 2022 Crohn's & Colitis Congress, so to catch the latest updates and strategies for improving IBD care for pediatric patients, tune in to hear Dr. Jennifer Caudle speak with Dr. Ashish Patel.
5 minutes | Apr 1, 2022
Crohn's & Colitis Congress 2022: Improving Moderate Ulcerative Colitis Care
Host: Jennifer Caudle, DO Guest: Alan C. Moss, MD When patients with moderate ulcerative colitis fail first-line therapy, it's important to know what to do next. And speaking with your patients about their risks and preferences is key. Join us as Dr. Alan Moss shares highlights from his presentation at the 2022 Crohn's & Colitis Congress on treatment considerations for patients with moderate ulcerative colitis.
11 minutes | Dec 10, 2021
Exploring the DINE-CD Study & the Importance of Diet for IBD Patients
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Caren Heller, MD, MBA For patients living with IBD, paying special attention to their nutrition is paramount. So which is more effective for IBD patients with mild-to-moderate symptoms: a Mediterranean style diet or the Special Carbohydrate diet? That’s what the Diets to Induce Remission in Crohn's Disease (DINE-CD) study sought to find out, and now the results are in. Join Dr. Peter Buch as he explores the study's key findings with Dr. Caren Heller, Chief Scientific Officer at the Crohn's and Colitis Foundation.
5 minutes | Jun 8, 2021
Endoscopic & Histological Assessment, Correlation, & Relapse in Clinically Quiescent Ulcerative Colitis
Guest: Jordan E. Axelrad, MD, MPH Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE) Mark T Osterman, Frank I Scott, Franz F Fogt, Erin D Gilroy, Susan Parrott, Joseph Galanko, Raymond Cross, Alan Moss, Hans H Herfarth, Peter D R Higgins Abstract Objective: It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse. Design: This multicenter prospective cohort study conducted by the Crohn's and Colitis Foundation Clinical Research Alliance included 100 adults with UC in clinical remission undergoing surveillance colonoscopy for dysplasia. Endoscopic activity was assessed using the Mayo endoscopic score (MES), ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS). Histology was assessed with the Riley index subcomponents, total Riley score, and basal plasmacytosis. Results: Only 5% of patients had an MES of 0, whereas 38% had a score of 2 to 3; using the UCEIS, the majority of patients had at least mild activity, …
6 minutes | Apr 8, 2021
Keeping CALM in Crohn’s Disease: An Exploration of Biomarker Cutoffs & Endoscopic Outcomes
Guest: Xiaohong Wang, MD, PhD Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study Walter Reinisch, Remo Panaccione, Peter Bossuyt, Filip Baert, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, William J Sandborn, Stefan Schreiber, Sofie Berg, Qian Zhou, Kristina Kligys, Ezequiel Neimark, Ahmed A Suleiman, Geert D'Haens, Jean-Frederic Colombel Background: CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone. The purpose of this post hoc analysis of CALM was to identify drivers of treatment escalation and evaluate the association between biomarker cutoff concentrations and endoscopic end points. Methods: The proportion of patients achieving CD Endoscopic Index of Severity (CDEIS) <4 and no deep ulcers 48 weeks after randomization was evaluated according to CRP <5 mg/L or ≥5 mg/L and FC <250 μg/g or ≥250 μg/g. Subgroup analyses were performed according to disease location, and sensitivity analyses were conducted in patients with elevated CRP and/or FC at baseline. The association between endoscopic end points and biomarker cutoffs was performed using χ …
8 minutes | Apr 2, 2021
Crohn’s & Colitis Congress 2021: Getting a Holistic View of IBD Diet Disparities & Well-Being
Guest: Tina Aswani Omprakash Wellness includes many different aspects, but what about mental health and the stressors of life that affect IBD patients? Joining Dr. Charles Turck to share key takeaways from a session at the 2021 Crohn’s and Colitis Congress called “Holistic View of IBD Diet Disparities and Well-Being” is Tina Aswani Omprakash, patient advocate and co-moderator of the session.
4 minutes | Feb 22, 2021
Crohn’s & Colitis Congress 2021: The Future of IBD Treatments
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Siddharth Singh, MD Dr. Charles Turck is joined by Dr. Siddharth Singh from the University of California, San Diego, to discuss emerging therapies for inflammatory bowel disease, or IBD, and share some highlights from the session “The Future of IBD Treatments” from Crohn’s & Colitis Congress 2021.
6 minutes | Feb 22, 2021
Crohn’s & Colitis Congress 2021: Challenges & Approaches to Managing IBD in the COVID-19 Era
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Frank Scott Dr. Charles Turck is joined by Dr. Frank Scott from the University of Colorado School of Medicine to share some highlights from his session, “Challenges and New Approaches to Managing IBD in the COVID-19 Era,” at Crohn’s & Colitis Congress 2021.
5 minutes | Jan 13, 2021
Crohn’s & Colitis Congress 2021: Incorporating IBD Therapies
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stephen Hanauer, MD Dr. Turck joins Dr. Stephen Hanauer of Northwestern University to discuss some of the highlights from his upcoming presentation at the 2021 Crohn’s & Colitis Congress, a Partnership of the Crohn’s and Colitis Foundation and the American Gastroenterological Association.
3 minutes | Jan 13, 2021
Crohn’s & Colitis Congress 2021: Caring for Children with IBD Amid the Pandemic
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Michael D. Kappelman, MD, MPH Pediatric care has evolved amid the COVID-19 pandemic. And when it comes to treating inflammatory bowel disorder, or IBD, gastroenterologists are faced with a unique set of challenges. Join us as Dr. Kappelman shares highlights of his presentation at the 2021 Crohn’s & Colitis Congress on what needs to be acknowledged while treating children with IBD during the COVID-19 pandemic.
5 minutes | Jan 13, 2021
Crohn’s & Colitis Congress 2021: Assessing the Role of Immunomodulators in IBD
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maria M. Oliva-Hemker, MD With current treatment approaches in mind, how do immunomodulators fit into the therapeutic landscape for inflammatory bowel disorders, or IBD? In preparation for the 2021 Crohn’s & Colitis Congress, Dr. Charles Turck speaks with Dr. Maria Oliva-Hemker from Johns Hopkins University School of Medicine about her presentation at the event.
4 minutes | Jan 13, 2021
Crohn’s & Colitis Congress 2021: Making the Most of IBD Treatment
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Marla C Dubinsky, MD Considering available therapeutics, how can we make the most of the drugs at our disposal for patients with inflammatory bowel disorders, or IBD? Ahead of her presentation at the 2021 Crohn's & Colitis Congress, Dr. Marla Dubinsky of Mount Sinai Kravis Children's Hospital discusses how current treatments can be used to not only ensure survival but also improve quality of life.
11 minutes | Dec 28, 2020
Exploring the Role of Cannabis in Inflammatory Bowel Disease
Host: Shira Johnson, MD Guest: Arun Swaminath, MD Recent studies have shown that smoking cannabis can improve some of the debilitating symptoms of inflammatory bowel disease, but the overall results are still inconclusive. Based on our current understanding, what is the impact of medical cannabis on IBD? Shira Johnson and Dr. Arun Swaminath, a practicing gastroenterologist at Northwell Health and Director of the Inflammatory Bowel Diseases Program at Lenox Hill Hospital, discuss the research of using cannabis to treat IBD.
12 minutes | Dec 28, 2020
Counteracting Chronic Pain in Patients with IBD
Host: Jennifer Caudle, DO Guest: Matthew Coates, MD, PhD Pain management is an unmet need for patients with IBD, or inflammatory bowel disease. How can we help them manage this excruciating symptom safely and effectively? Dr. Matthew Coates, a physician scientist at Penn State Health Gastroenterology, joins Dr. Jennifer Caudle to identify what causes chronic pain and how we can best serve our patients.
13 minutes | Dec 28, 2020
FMT & the Growing Treatment Landscape for IBD
Host: Stacy Kahn, MD Guest: Jessica Allegretti, MD, MPH FMT, or fecal microbiota transplantation, could be the therapeutic solution for patients with Crohn’s disease or ulcerative colitis. But what exactly is this treatment, and how is it changing the treatment landscape for patients with inflammatory bowel disease? Dr. Stacy Kahn, from Boston Children’s Hospital, is joined by Dr. Jessica Allegretti, from Brigham & Women’s Hospital, to discuss this new treatment option for IBD patients.
3 minutes | Aug 27, 2020
Keys to Approaching Difficult Cases in Crohn’s Disease
Guest: Iris Dotan, MD Here to share his insights on difficult cases in Crohn’s disease is Dr. Eytan Mor from the Rabin Medical Center in Israel. Dr. Mor defines for us what a difficult case in Crohn’s disease looks like and the various treatment options that are available. Published August 27, 2020
3 minutes | Aug 27, 2020
Understanding the Importance of Nutrition in IBD
Guest: James Lindsay PhD, BM BCh, FRCP Nutrition plays an important role in inflammatory bowel disease, but it’s important to instill in patients the understanding that even though a healthy diet can help reduce symptoms, it doesn’t mean that the disease itself has improved. Here to share how he talks about nutrition with his patients and other key management strategies like the low FODMAP diet is Dr. James Lindsay, Professor of Inflammatory Bowel Disease at Barts Health in London. Published August 27, 2020
3 minutes | Aug 7, 2020
How to Start a Path in Clinical Research
Guest: Siddharth Singh, MD There are multiple resources at hand to help guide you toward a career in clinical research, and here to share them along with his overall experience in the field is Dr. Sid Singh, clinical gastroenterologist at UC San Diego. Published August 7, 2020
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2022